{"ticker": {"uuid": "7cd48e64-c76c-42d6-aff9-7abd0b247eec", "symbol": "INTS", "name": "Intensity Therapeutics, Inc. Common stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Intensity Therapeutics restarts 61-patient breast cancer trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNOFlpZUxTVTFFS0xRbTZSbFNPaThyZ3hkZkMtUU5pQkQ4OU5XVXBweVhKcFdGZ0VmRTdyay1oU1hQZnFoT1RvOUtqalV6SXVnN3lwa1VMRTRVaUN6WUZkVkkxWlJQNGV1QUR5N1pNNWpGT1BGOXgyc3d1RmUwRnUwQXFRdDllMm42SXRGTk92NU5VdHVCczFhQjBLQk5ZNTRNNXc0?oc=5", "source_name": "grafa.com", "published_at": "2026-07-15T16:32:00+00:00", "published_display": "15 Jul 2026 16:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Resumes Dosing in Phase 2 Trial for Investigational Cancer Therapy in Switzerland", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/intensity-therapeutics-resumes-dosing-phase-121506284.html", "source_name": "MT Newswires", "published_at": "2026-07-15T12:15:06+00:00", "published_display": "15 Jul 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics resumes patient dosing in Swiss trial", "summary": "Intensity Therapeutics Inc. has resumed patient dosing in its INVINCIBLE-4 Study in Switzerland for early-stage, operable triple-negative breast cancer, following a temporary pause due to skin irritation. The company's stock has faced volatility, but analysts maintain a bullish o", "url": "https://www.investing.com/news/company-news/intensity-therapeutics-resumes-patient-dosing-in-swiss-trial-93CH-4793094", "source_name": "Investing.com", "published_at": "2026-07-15T12:39:56", "published_display": "15 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)", "summary": "Intensity Therapeutics has restarted patient treatment in its Phase 2 clinical trial (INVINCIBLE-4 Study) for presurgical triple-negative breast cancer (TNBC) in Switzerland. The trial, using INT230-6, was resumed after a protocol amendment addressed skin irritation issues by adj", "url": "https://www.prnewswire.com/news-releases/intensity-therapeutics-inc-restarts-patient-treatment-in-the-randomized-presurgical-triple-negative-breast-cancer-phase-2-clinical-trial-invincible-4-study-302825854.html", "source_name": "PR Newswire", "published_at": "2026-07-15T11:39:56", "published_display": "15 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Intensity Therapeutics (INTS) Surges 6.6%: Testing Key Resistance After Strong Session - Inverse ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNUk5MWHU0SHh2ZHFxZnlka0VtZ0d3UXJUUGx3VmdyRGFfSnhBLUZ2TnViaGJEOWo2SVBPZy1ORlpHYXlMN3l5Z2ZuUmZoemR6enF4RXZKTmQzYjVkYzBhVnFVdWp6cmpNZmJHRk9xRHFSbGpCNnljMk1XSE1SdjZEb1ZXU1BoLVB3a05YcEtGLVNzY0J5UzN5UmtiMS16bERFdmpSbTBhbTRCM18zN1dmbTZTdmp6NFhBeFBDU3M2MUU?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T18:40:28+00:00", "published_display": "07 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INTS SEC Filings - INTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for SEC filings related to Intensity Therapeutics (Ticker: INTS), a clinical-stage biotechnology company. It includes access to 10-K, 10-Q, 8-K reports, and insider trading forms, with the most recent filing being a Form 4 on July 2, 20", "url": "https://www.stocktitan.net/sec-filings/INTS/page-4.html", "source_name": "Stock Titan", "published_at": "2026-07-03T22:40:18", "published_display": "03 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics (INTS) Edges Lower, Testing Key Support at $3.91 - Breakout Stock Alerts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQcm1SOE9KTl9hLTdXRHpmVHB6dHJtUkdTSmRwSTVEOEVVRHNuTDdGdkFHdkpKYWRfcnRJSVRYYkdZUkhEUXAxZE1pcTZjbUZFVzAyMnNpaUt6QXI2MHdjbFdGbTlqVnhLbW1wcUVfeUY3cXlsSWhkaFlpeFoxbkhtMGpBWWl2OUx6RHlkMk1ZXzByVU5YbjFzem5NekRfUThSekhKWl9QZXJlN010TmxaNm9BMA?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics (INTS) CFO adds 1,093 ESPP shares at discount", "summary": "Intensity Therapeutics' Chief Financial Officer, Joseph Talamo, acquired 1,093 shares of common stock through the company's Employee Stock Purchase Plan at a discounted price of $3.485 per share. This purchase, made on June 30, 2026, increased his direct holdings to 2,239 shares ", "url": "https://www.stocktitan.net/sec-filings/INTS/form-4-intensity-therapeutics-inc-insider-trading-activity-589248d466d2.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:40:53", "published_display": "01 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ESPP purchase adds shares for Intensity Therapeutics (NASDAQ: INTS) officer", "summary": "John M. Wesolowski, Principal Accounting Officer at Intensity Therapeutics (NASDAQ: INTS), acquired 3,688 shares through the company's Amended and Restated 2024 Employee Stock Purchase Plan. The shares were purchased at $3.485 each, increasing his direct holdings to 7,102 shares.", "url": "https://www.stocktitan.net/sec-filings/INTS/form-4-intensity-therapeutics-inc-insider-trading-activity-1ab8b203b4c2.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:40:53", "published_display": "01 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics updates INT230-6 cancer trials", "summary": "Intensity Therapeutics (NASDAQ:INTS) has provided a mid-year update on its INT230-6 cancer therapy, detailing advancements in Phase 2/3 breast cancer and Phase 3 soft tissue sarcoma trials. Preliminary data from triple-negative breast cancer studies showed improved pathological c", "url": "https://grafa.com/en/news/united-states/intensity-therapeutics-ints-int230-6-midyear-update-2026", "source_name": "grafa.com", "published_at": "2026-07-01T12:20:00", "published_display": "01 Jul 2026 12:20", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6", "summary": "Intensity Therapeutics has issued a mid-year update for 2026, detailing the advancement of its late-stage development programs for INT230-6 in soft tissue sarcoma and presurgical triple-negative breast cancer. The company highlights favorable preliminary clinical observations, si", "url": "https://www.prnewswire.com/news-releases/intensity-therapeutics-provides-mid-year-update-highlighting-late-stage-development-programs-and-strategic-partnering-opportunities-for-int230-6-302815303.html", "source_name": "PR Newswire", "published_at": "2026-07-01T11:40:33", "published_display": "01 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics resumes cancer trials, seeks INT230-6 partners", "summary": "Intensity Therapeutics provided a mid-year 2026 update on its INT230-6 intratumoral cancer therapy, highlighting progress in Phase 2/3 breast cancer and Phase 3 soft tissue sarcoma trials. The company reported peer-reviewed data, active partnering discussions, and established a $", "url": "https://www.stocktitan.net/news/INTS/intensity-therapeutics-provides-mid-year-update-highlighting-late-fva6yw10d4bv.html", "source_name": "Stock Titan", "published_at": "2026-06-30T06:12:20", "published_display": "30 Jun 2026 06:12", "sentiment": "positive", "sentiment_pct": 84, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Intensity Therapeutics, Inc. \u2013 NASDAQ:INTS", "summary": "This page from TradingView displays financial information for Intensity Therapeutics, Inc. (NASDAQ: INTS), specifically focusing on its price-to-earnings forward metric. The content indicates that market data is provided by ICE Data Services and reference data by FactSet, with SE", "url": "https://www.tradingview.com/symbols/NASDAQ-INTS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T12:39:17", "published_display": "27 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Intensity Therapeutics, Inc. \u2013 NASDAQ:INTS", "summary": "This article provides a brief financial overview of Intensity Therapeutics, Inc. (NASDAQ: INTS), focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication, with no trades occurring. The content is presented within the Trading", "url": "https://www.tradingview.com/symbols/NASDAQ-INTS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:39:57", "published_display": "27 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Intensity Therapeutics, Inc. \u2013 NASDAQ:INTS", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOdC1ISklWTmlLb05qVmxuZzVEQlQ1dkdDYzJSdnl2X21wejB2Q05QMDBJVXhhb1V3VVZKVUpZUkNVRUVZRmtFLWRmTFB0dmZJS3loS0RXM1ZNdDlPaXRYdktRbG4xQzltb2RXWjB3c1d5a1h5N1cxSzB5b1Naa2kwN0hzYlhKZ0QtVTNxMUVzUnBxcXI4bGVnMWpKSDA?oc=5", "source_name": "TradingView", "published_at": "2026-06-27T05:36:04+00:00", "published_display": "27 Jun 2026 05:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics, Inc. Actuals & Estimates (NASDAQ:INTS)", "summary": "This article provides an overview of Intensity Therapeutics, Inc. (NASDAQ: INTS) stock performance, financial estimates, and analyst forecasts. It covers current stock price, volatility, market capitalization, upcoming earnings dates, and historical financial data such as revenue", "url": "https://www.tradingview.com/symbols/NASDAQ-INTS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T22:39:57", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics, Inc. Actuals & Estimates (BOATS:INTS)", "summary": "This article provides financial actuals and estimates for Intensity Therapeutics, Inc. (INTS) traded on BOATS. It includes information on the stock ticker, analyst price forecasts ranging from $12.00 to $32.00, historical high and low prices, upcoming earnings reports, and detail", "url": "https://www.tradingview.com/symbols/BOATS-INTS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:36", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Intensity Therapeutics, Inc. \u2013 NASDAQ:INTS", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Intensity Therapeutics, Inc. (NASDAQ: INTS). It appears to be a financial data point from TradingView, which aggregates market and reference data from sources like ICE Data Services and FactSet. The conten", "url": "https://www.tradingview.com/symbols/NASDAQ-INTS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T20:10:36", "published_display": "26 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INTS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Intensity Therapeutics, Inc. (INTS) stock, including analyst price targets, current stock performance, and financial data. It highlights that analysts have a maximum price estimate of $32.00 and a minimum of $12.00 for INTS. The piece also inc", "url": "https://www.tradingview.com/symbols/NASDAQ-INTS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T18:10:36", "published_display": "26 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting", "summary": "Intensity Therapeutics, Inc. held its annual meeting where stockholders approved several key proposals. These included the election of two Class III directors, ratification of EisnerAmper LLP as independent public accounting firm, and approval of amendments to stock incentive pla", "url": "https://www.theglobeandmail.com/investing/markets/stocks/INTS-Q/pressreleases/2524732/intensity-therapeutics-stockholders-approve-proposals-at-annual-meeting/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T21:09:04", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc (INTS) Institutional Confidence", "summary": "The article provides an overview of institutional confidence in Intensity Therapeutics Inc (INTS), detailing key institutional shareholders and their recent activity. It lists the shares held and the percentage change for several firms, including Bender (Lewis H), Sapient Capital", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ints/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:31", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Intensity Therapeutics Inc (INTS) has a \"Buy\" rating from 5 analysts, with a target price of $3.00, representing a significant upside. The company's previous quarter's EPS was -$1.31, missing the market expectation of -$0.96, but the next quarter's EPS is projected to be -$0.77. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ints/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:31", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc (INTS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Intensity Therapeutics Inc. (INTS), focusing on its PE, PB, and fair value. However, it notes that relevant data for these metrics have not yet been disclosed by the company, limiting a comprehensive valuation based on these specific", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ints/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:31", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics shareholders approve board proposals at annual meeting", "summary": "Intensity Therapeutics (NASDAQ:INTS) shareholders approved all proposals at their annual meeting, including the election of two Class III directors, the ratification of EisnerAmper LLP as the accounting firm, and amendments to the 2021 Stock Incentive Plan and 2024 Employee Stock", "url": "https://www.investing.com/news/sec-filings/intensity-therapeutics-shareholders-approve-board-proposals-at-annual-meeting-93CH-4746203", "source_name": "Investing.com", "published_at": "2026-06-17T20:09:31", "published_display": "17 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses Intensity Therapeutics Inc (INTS) and its revenue breakdown by business segments and regions. However, the core message is that the relevant financial data for these breakdowns has not yet been disclosed by the company. The article provides current stock inf", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ints/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:41:10", "published_display": "17 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc (INTS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of Intensity Therapeutics Inc (INTS) shareholder structure, listing major individual and institutional holders and their respective proportions. It also includes institutional shareholding trends over several quarters and recent sharehol", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ints/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T18:41:10", "published_display": "17 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics shareholders approve board proposals at annual meeting By Investing.com", "summary": "Intensity Therapeutics shareholders have approved all proposals at their annual meeting, including the election of two Class III directors, ratification of their accounting firm, and amendments to their stock incentive and employee stock purchase plans. This comes as the biotech ", "url": "https://m.za.investing.com/news/sec-filings/intensity-therapeutics-shareholders-approve-board-proposals-at-annual-meeting-93CH-4331885?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-16T23:39:17", "published_display": "16 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics (NASDAQ: INTS) OKs share plan increases and board elections", "summary": "Intensity Therapeutics, Inc. (NASDAQ: INTS) held its 2026 annual stockholder meeting, where shareholders approved increases to the 2021 Stock Incentive Plan and 2024 Employee Stock Purchase Plan. Shareholders also elected Dr. Emer Leahy and Lewis H. Bender as Class III directors ", "url": "https://www.stocktitan.net/sec-filings/INTS/8-k-intensity-therapeutics-inc-reports-material-event-5e08cb00e890.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:39:17", "published_display": "16 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INTS: All proposals, including director elections and stock plan amendments, were approved by majority vote", "summary": "Intensity Therapeutics, Inc. (INTS) held its AGM 2026 where all proposals were approved by a majority vote. This included the re-election of two directors, the ratification of the auditor, and amendments to stock plans. No questions were raised during the Q&A session.", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3598893:0-ints-all-proposals-including-director-elections-and-stock-plan-amendments-were-approved-by-majority-vote/", "source_name": "TradingView", "published_at": "2026-06-16T15:10:29", "published_display": "16 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INTS | Intensity Therapeutics, Inc. Common Insider Trading", "summary": "This article provides an overview of Intensity Therapeutics, Inc. (INTS) stock information, focusing on insider trading, institutional holdings, and other financial data available through Quiver Quantitative. It details the absence of recent congressional or quarterly net insider", "url": "https://www.quiverquant.com/stock/INTS/insiders/", "source_name": "Quiver Quantitative", "published_at": "2026-05-30T07:39:03", "published_display": "30 May 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeXFqZ2NOMGh3NGlFLVpYa3JMMnZaS29mYXJjdE9YcXFxcjV2bEp0dUp3ZllJVXlZeHhvYm5ISDV3VzF5WWZlSk9qREFiYm1HXzhMZ2ZfQ01heVVnWklTS2p5ZjFTYk80U01UQ3JxX1l4eXRHWVlCSUlQQVY5RTNBemNfVU0zMlJGRXRXaXJheTJxOFZFMW00RjMxMGt0ZHBHSXYwbThQdm4?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benchmark reiterates Intensity Therapeutics stock rating on clinical progress", "summary": "Benchmark has maintained a \"Speculative Buy\" rating and a $12.00 price target for Intensity Therapeutics (NASDAQ:INTS) after the company's first-quarter results and clinical updates. The biotechnology firm received approval to resume enrollment in trials for its INT230-6 treatmen", "url": "https://m.investing.com/news/analyst-ratings/benchmark-reiterates-intensity-therapeutics-stock-rating-on-clinical-progress-93CH-4701697?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-20T14:39:11", "published_display": "20 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech behind INT230-6 honored for novel tumor-killing approach", "summary": "Intensity Therapeutics (Nasdaq: INTS) has been named Cancer Treatment Technology Innovator of the Year 2026 \u2013 USA by GHP Magazine for its proprietary intratumoral cancer therapies. The award recognizes the company's non-covalent drug-conjugation platform, which has shown encourag", "url": "https://www.stocktitan.net/news/INTS/intensity-therapeutics-recognized-with-ghp-magazine-s-2026-ra983f6gyao1.html", "source_name": "Stock Titan", "published_at": "2026-05-18T09:38:51", "published_display": "18 May 2026 09:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INTS News | INTENSITY THERAPEUTICS INC (NASDAQ:INTS)", "summary": "This article provides recent news and analysis for Intensity Therapeutics Inc. (NASDAQ: INTS). Key updates include the company's Q1 2026 results where EPS beat expectations despite no revenue, and its recognition with GHP Magazine's 2026 Healthcare & Pharmaceutical Award. The cur", "url": "https://www.chartmill.com/stock/quote/INTS/news", "source_name": "ChartMill", "published_at": "2026-05-18T08:39:55", "published_display": "18 May 2026 08:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/intensity-therapeutics-recognized-ghp-magazines-120000408.html", "source_name": "PR Newswire", "published_at": "2026-05-14T12:00:00+00:00", "published_display": "14 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxOcnI2b2o2NThtb2x4andUM1JIOWtLSnJVLTRJRXRqZGNEV1ZoYV9GckFaSktSaEJwWWEzM3BOMHRaV1hqUEFQaUUxMUJXY2VCM0FERGhpQ0dQNzY4YTF3azVvRUh1c0twaDZFMXpJWnAtNEs5SGpGSDhxazNnLXZCNU16Z3ZsZVk5VC1rR1hVdTJLUXFvUjd3Rlh0dV9OS3VUclN0aU54Qm9kZHZRbERXRkpERkdfUDhWVDBZMzdGOUo5MnFFSzBWRWp5MWRmb0RaODB4STk2N1RIR3lBQzJoYmRha3o4Y21j?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNWFRzZU1BV2FpNlJ3ejBkOE1FT2tEbXB3WEhVLVVhWWpaSEFSYVozUHpTcWFyLXl6N25hNmVpMjhLWFBMcmtvcnBlM1VVcFBTOG1HdTZsY2R0ZThnOFpuQ01DcUhabWdfZDd1aUMzaE93SHpROG16RDR0Y2M4WWJVR3JBYXd0TmZHc3dyTXh1bDg4TkNKMTMwZ1pzeWtSRnFPTkszcw?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbkZISmFmQ0szWHhCNkNJMjRadXhURm92R3lwWk52aHlOdEh6aV9UaUR1UV9ka1RzVk42ZFFaR1NEUDhDZThpb0pqZUhFZFRxa0paZkZCSERDelZxMktxZHRYV08zR2p5dEoyRjhmbnRnWXU3ZEhtQmNzZEtNVzdkdUtVa3lhRTdpNERycXFsNGJ0R1JiazFqa3E1TF90S0s1ZUZOQmw1NDA?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did INTS Stock Plummet 25% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNjlGNWltUUNZSXdYOVctWGlYd1dHQWxoTVVnaDdPNTF1MDNFTXVDZWhHYXRRUjQxM3hUdnFGTVdSN0lhX2lvVzRxV1dYVWgwT0xBdEI0el9TYkVORmpNLVoxS09UcURYNDI1aVloUkZFX1E1b0VoS3Z0RXd4YmRzV3NhNEpJbjlrUVJhb2xqY0xQQ3N3NE1oNXI5Nk00S1pSejJBZnZ4VkZ6UmM?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Announces Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPTDdTNDBoTm9MM0p0dWFxQ09HeXB3c3JiOW9wa2JKRXBsUUM0YkIwd18yV3ZsRHpHS0cyREN4UXFERDU0VElHR0Jid1NvbXJSc3o2ZHlVR1NNWTVWd3dYY3hDWmlfMkVVdFBPcnZhbEc0X2E4MndBNTdCNWFTSDNuaTZEMnBnM1JnbXJ2VmRtVzhzaXZ6NHVVaWVSTHRTN2ZPVnEtVjZydktOeUd3?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxNZXRXUzFyektQVkdNcUZVVFhQbFI4WGFVekVWNFg0N1VlWVJJeTgwZEN3QUlENk41dzlOeGlsb0xZenltQkw0cGw3aDEyal9lWWMtQm1ZZXA5eHpnU0trWDZRNThfT1dPTXFVZGd0akJGUmVsVVQ5NjM0RUg3U0Zha0FNdGVPM3JRLWVBbmExam5xeDg3bUpCMmVZTnA3dzJvdEZDQzQ0dkpsb19WcFQ4ZmxVWjg3RWJxYW5YRkd1NGlfZE02aEhTbUp2QTd4TEFOMS1MX2dCU1hvRnFzeXNmX2RoWHVRM1laMUV3dV90QWRKZlBOMWNhbGM4Y2Q?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Intensity Therapeutics restarts 61-patient breast cancer trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNOFlpZUxTVTFFS0xRbTZSbFNPaThyZ3hkZkMtUU5pQkQ4OU5XVXBweVhKcFdGZ0VmRTdyay1oU1hQZnFoT1RvOUtqalV6SXVnN3lwa1VMRTRVaUN6WUZkVkkxWlJQNGV1QUR5N1pNNWpGT1BGOXgyc3d1RmUwRnUwQXFRdDllMm42SXRGTk92NU5VdHVCczFhQjBLQk5ZNTRNNXc0?oc=5", "source_name": "grafa.com", "published_at": "2026-07-15T16:32:00+00:00", "published_display": "15 Jul 2026 16:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Resumes Dosing in Phase 2 Trial for Investigational Cancer Therapy in Switzerland", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/intensity-therapeutics-resumes-dosing-phase-121506284.html", "source_name": "MT Newswires", "published_at": "2026-07-15T12:15:06+00:00", "published_display": "15 Jul 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics resumes patient dosing in Swiss trial", "summary": "Intensity Therapeutics Inc. has resumed patient dosing in its INVINCIBLE-4 Study in Switzerland for early-stage, operable triple-negative breast cancer, following a temporary pause due to skin irritation. The company's stock has faced volatility, but analysts maintain a bullish o", "url": "https://www.investing.com/news/company-news/intensity-therapeutics-resumes-patient-dosing-in-swiss-trial-93CH-4793094", "source_name": "Investing.com", "published_at": "2026-07-15T12:39:56", "published_display": "15 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)", "summary": "Intensity Therapeutics has restarted patient treatment in its Phase 2 clinical trial (INVINCIBLE-4 Study) for presurgical triple-negative breast cancer (TNBC) in Switzerland. The trial, using INT230-6, was resumed after a protocol amendment addressed skin irritation issues by adj", "url": "https://www.prnewswire.com/news-releases/intensity-therapeutics-inc-restarts-patient-treatment-in-the-randomized-presurgical-triple-negative-breast-cancer-phase-2-clinical-trial-invincible-4-study-302825854.html", "source_name": "PR Newswire", "published_at": "2026-07-15T11:39:56", "published_display": "15 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics (INTS) Surges 6.6%: Testing Key Resistance After Strong Session - Inverse ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNUk5MWHU0SHh2ZHFxZnlka0VtZ0d3UXJUUGx3VmdyRGFfSnhBLUZ2TnViaGJEOWo2SVBPZy1ORlpHYXlMN3l5Z2ZuUmZoemR6enF4RXZKTmQzYjVkYzBhVnFVdWp6cmpNZmJHRk9xRHFSbGpCNnljMk1XSE1SdjZEb1ZXU1BoLVB3a05YcEtGLVNzY0J5UzN5UmtiMS16bERFdmpSbTBhbTRCM18zN1dmbTZTdmp6NFhBeFBDU3M2MUU?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-07T18:40:28+00:00", "published_display": "07 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INTS SEC Filings - INTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for SEC filings related to Intensity Therapeutics (Ticker: INTS), a clinical-stage biotechnology company. It includes access to 10-K, 10-Q, 8-K reports, and insider trading forms, with the most recent filing being a Form 4 on July 2, 20", "url": "https://www.stocktitan.net/sec-filings/INTS/page-4.html", "source_name": "Stock Titan", "published_at": "2026-07-03T22:40:18", "published_display": "03 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics (INTS) Edges Lower, Testing Key Support at $3.91 - Breakout Stock Alerts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQcm1SOE9KTl9hLTdXRHpmVHB6dHJtUkdTSmRwSTVEOEVVRHNuTDdGdkFHdkpKYWRfcnRJSVRYYkdZUkhEUXAxZE1pcTZjbUZFVzAyMnNpaUt6QXI2MHdjbFdGbTlqVnhLbW1wcUVfeUY3cXlsSWhkaFlpeFoxbkhtMGpBWWl2OUx6RHlkMk1ZXzByVU5YbjFzem5NekRfUThSekhKWl9QZXJlN010TmxaNm9BMA?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics (INTS) CFO adds 1,093 ESPP shares at discount", "summary": "Intensity Therapeutics' Chief Financial Officer, Joseph Talamo, acquired 1,093 shares of common stock through the company's Employee Stock Purchase Plan at a discounted price of $3.485 per share. This purchase, made on June 30, 2026, increased his direct holdings to 2,239 shares ", "url": "https://www.stocktitan.net/sec-filings/INTS/form-4-intensity-therapeutics-inc-insider-trading-activity-589248d466d2.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:40:53", "published_display": "01 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ESPP purchase adds shares for Intensity Therapeutics (NASDAQ: INTS) officer", "summary": "John M. Wesolowski, Principal Accounting Officer at Intensity Therapeutics (NASDAQ: INTS), acquired 3,688 shares through the company's Amended and Restated 2024 Employee Stock Purchase Plan. The shares were purchased at $3.485 each, increasing his direct holdings to 7,102 shares.", "url": "https://www.stocktitan.net/sec-filings/INTS/form-4-intensity-therapeutics-inc-insider-trading-activity-1ab8b203b4c2.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:40:53", "published_display": "01 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics updates INT230-6 cancer trials", "summary": "Intensity Therapeutics (NASDAQ:INTS) has provided a mid-year update on its INT230-6 cancer therapy, detailing advancements in Phase 2/3 breast cancer and Phase 3 soft tissue sarcoma trials. Preliminary data from triple-negative breast cancer studies showed improved pathological c", "url": "https://grafa.com/en/news/united-states/intensity-therapeutics-ints-int230-6-midyear-update-2026", "source_name": "grafa.com", "published_at": "2026-07-01T12:20:00", "published_display": "01 Jul 2026 12:20", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6", "summary": "Intensity Therapeutics has issued a mid-year update for 2026, detailing the advancement of its late-stage development programs for INT230-6 in soft tissue sarcoma and presurgical triple-negative breast cancer. The company highlights favorable preliminary clinical observations, si", "url": "https://www.prnewswire.com/news-releases/intensity-therapeutics-provides-mid-year-update-highlighting-late-stage-development-programs-and-strategic-partnering-opportunities-for-int230-6-302815303.html", "source_name": "PR Newswire", "published_at": "2026-07-01T11:40:33", "published_display": "01 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics resumes cancer trials, seeks INT230-6 partners", "summary": "Intensity Therapeutics provided a mid-year 2026 update on its INT230-6 intratumoral cancer therapy, highlighting progress in Phase 2/3 breast cancer and Phase 3 soft tissue sarcoma trials. The company reported peer-reviewed data, active partnering discussions, and established a $", "url": "https://www.stocktitan.net/news/INTS/intensity-therapeutics-provides-mid-year-update-highlighting-late-fva6yw10d4bv.html", "source_name": "Stock Titan", "published_at": "2026-06-30T06:12:20", "published_display": "30 Jun 2026 06:12", "sentiment": "positive", "sentiment_pct": 84, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Intensity Therapeutics, Inc. \u2013 NASDAQ:INTS", "summary": "This page from TradingView displays financial information for Intensity Therapeutics, Inc. (NASDAQ: INTS), specifically focusing on its price-to-earnings forward metric. The content indicates that market data is provided by ICE Data Services and reference data by FactSet, with SE", "url": "https://www.tradingview.com/symbols/NASDAQ-INTS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T12:39:17", "published_display": "27 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Intensity Therapeutics, Inc. \u2013 NASDAQ:INTS", "summary": "This article provides a brief financial overview of Intensity Therapeutics, Inc. (NASDAQ: INTS), focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of publication, with no trades occurring. The content is presented within the Trading", "url": "https://www.tradingview.com/symbols/NASDAQ-INTS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:39:57", "published_display": "27 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Intensity Therapeutics, Inc. \u2013 NASDAQ:INTS", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOdC1ISklWTmlLb05qVmxuZzVEQlQ1dkdDYzJSdnl2X21wejB2Q05QMDBJVXhhb1V3VVZKVUpZUkNVRUVZRmtFLWRmTFB0dmZJS3loS0RXM1ZNdDlPaXRYdktRbG4xQzltb2RXWjB3c1d5a1h5N1cxSzB5b1Naa2kwN0hzYlhKZ0QtVTNxMUVzUnBxcXI4bGVnMWpKSDA?oc=5", "source_name": "TradingView", "published_at": "2026-06-27T05:36:04+00:00", "published_display": "27 Jun 2026 05:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics, Inc. Actuals & Estimates (NASDAQ:INTS)", "summary": "This article provides an overview of Intensity Therapeutics, Inc. (NASDAQ: INTS) stock performance, financial estimates, and analyst forecasts. It covers current stock price, volatility, market capitalization, upcoming earnings dates, and historical financial data such as revenue", "url": "https://www.tradingview.com/symbols/NASDAQ-INTS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T22:39:57", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics, Inc. Actuals & Estimates (BOATS:INTS)", "summary": "This article provides financial actuals and estimates for Intensity Therapeutics, Inc. (INTS) traded on BOATS. It includes information on the stock ticker, analyst price forecasts ranging from $12.00 to $32.00, historical high and low prices, upcoming earnings reports, and detail", "url": "https://www.tradingview.com/symbols/BOATS-INTS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:36", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Intensity Therapeutics, Inc. \u2013 NASDAQ:INTS", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Intensity Therapeutics, Inc. (NASDAQ: INTS). It appears to be a financial data point from TradingView, which aggregates market and reference data from sources like ICE Data Services and FactSet. The conten", "url": "https://www.tradingview.com/symbols/NASDAQ-INTS/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T20:10:36", "published_display": "26 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INTS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Intensity Therapeutics, Inc. (INTS) stock, including analyst price targets, current stock performance, and financial data. It highlights that analysts have a maximum price estimate of $32.00 and a minimum of $12.00 for INTS. The piece also inc", "url": "https://www.tradingview.com/symbols/NASDAQ-INTS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T18:10:36", "published_display": "26 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Stockholders Approve Proposals at Annual Meeting", "summary": "Intensity Therapeutics, Inc. held its annual meeting where stockholders approved several key proposals. These included the election of two Class III directors, ratification of EisnerAmper LLP as independent public accounting firm, and approval of amendments to stock incentive pla", "url": "https://www.theglobeandmail.com/investing/markets/stocks/INTS-Q/pressreleases/2524732/intensity-therapeutics-stockholders-approve-proposals-at-annual-meeting/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T21:09:04", "published_display": "18 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc (INTS) Institutional Confidence", "summary": "The article provides an overview of institutional confidence in Intensity Therapeutics Inc (INTS), detailing key institutional shareholders and their recent activity. It lists the shares held and the percentage change for several firms, including Bender (Lewis H), Sapient Capital", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ints/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:31", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Intensity Therapeutics Inc (INTS) has a \"Buy\" rating from 5 analysts, with a target price of $3.00, representing a significant upside. The company's previous quarter's EPS was -$1.31, missing the market expectation of -$0.96, but the next quarter's EPS is projected to be -$0.77. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ints/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:31", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc (INTS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Intensity Therapeutics Inc. (INTS), focusing on its PE, PB, and fair value. However, it notes that relevant data for these metrics have not yet been disclosed by the company, limiting a comprehensive valuation based on these specific", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ints/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:31", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics shareholders approve board proposals at annual meeting", "summary": "Intensity Therapeutics (NASDAQ:INTS) shareholders approved all proposals at their annual meeting, including the election of two Class III directors, the ratification of EisnerAmper LLP as the accounting firm, and amendments to the 2021 Stock Incentive Plan and 2024 Employee Stock", "url": "https://www.investing.com/news/sec-filings/intensity-therapeutics-shareholders-approve-board-proposals-at-annual-meeting-93CH-4746203", "source_name": "Investing.com", "published_at": "2026-06-17T20:09:31", "published_display": "17 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses Intensity Therapeutics Inc (INTS) and its revenue breakdown by business segments and regions. However, the core message is that the relevant financial data for these breakdowns has not yet been disclosed by the company. The article provides current stock inf", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ints/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:41:10", "published_display": "17 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc (INTS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of Intensity Therapeutics Inc (INTS) shareholder structure, listing major individual and institutional holders and their respective proportions. It also includes institutional shareholding trends over several quarters and recent sharehol", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ints/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T18:41:10", "published_display": "17 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics shareholders approve board proposals at annual meeting By Investing.com", "summary": "Intensity Therapeutics shareholders have approved all proposals at their annual meeting, including the election of two Class III directors, ratification of their accounting firm, and amendments to their stock incentive and employee stock purchase plans. This comes as the biotech ", "url": "https://m.za.investing.com/news/sec-filings/intensity-therapeutics-shareholders-approve-board-proposals-at-annual-meeting-93CH-4331885?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-16T23:39:17", "published_display": "16 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics (NASDAQ: INTS) OKs share plan increases and board elections", "summary": "Intensity Therapeutics, Inc. (NASDAQ: INTS) held its 2026 annual stockholder meeting, where shareholders approved increases to the 2021 Stock Incentive Plan and 2024 Employee Stock Purchase Plan. Shareholders also elected Dr. Emer Leahy and Lewis H. Bender as Class III directors ", "url": "https://www.stocktitan.net/sec-filings/INTS/8-k-intensity-therapeutics-inc-reports-material-event-5e08cb00e890.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:39:17", "published_display": "16 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INTS: All proposals, including director elections and stock plan amendments, were approved by majority vote", "summary": "Intensity Therapeutics, Inc. (INTS) held its AGM 2026 where all proposals were approved by a majority vote. This included the re-election of two directors, the ratification of the auditor, and amendments to stock plans. No questions were raised during the Q&A session.", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3598893:0-ints-all-proposals-including-director-elections-and-stock-plan-amendments-were-approved-by-majority-vote/", "source_name": "TradingView", "published_at": "2026-06-16T15:10:29", "published_display": "16 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INTS | Intensity Therapeutics, Inc. Common Insider Trading", "summary": "This article provides an overview of Intensity Therapeutics, Inc. (INTS) stock information, focusing on insider trading, institutional holdings, and other financial data available through Quiver Quantitative. It details the absence of recent congressional or quarterly net insider", "url": "https://www.quiverquant.com/stock/INTS/insiders/", "source_name": "Quiver Quantitative", "published_at": "2026-05-30T07:39:03", "published_display": "30 May 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeXFqZ2NOMGh3NGlFLVpYa3JMMnZaS29mYXJjdE9YcXFxcjV2bEp0dUp3ZllJVXlZeHhvYm5ISDV3VzF5WWZlSk9qREFiYm1HXzhMZ2ZfQ01heVVnWklTS2p5ZjFTYk80U01UQ3JxX1l4eXRHWVlCSUlQQVY5RTNBemNfVU0zMlJGRXRXaXJheTJxOFZFMW00RjMxMGt0ZHBHSXYwbThQdm4?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benchmark reiterates Intensity Therapeutics stock rating on clinical progress", "summary": "Benchmark has maintained a \"Speculative Buy\" rating and a $12.00 price target for Intensity Therapeutics (NASDAQ:INTS) after the company's first-quarter results and clinical updates. The biotechnology firm received approval to resume enrollment in trials for its INT230-6 treatmen", "url": "https://m.investing.com/news/analyst-ratings/benchmark-reiterates-intensity-therapeutics-stock-rating-on-clinical-progress-93CH-4701697?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-20T14:39:11", "published_display": "20 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech behind INT230-6 honored for novel tumor-killing approach", "summary": "Intensity Therapeutics (Nasdaq: INTS) has been named Cancer Treatment Technology Innovator of the Year 2026 \u2013 USA by GHP Magazine for its proprietary intratumoral cancer therapies. The award recognizes the company's non-covalent drug-conjugation platform, which has shown encourag", "url": "https://www.stocktitan.net/news/INTS/intensity-therapeutics-recognized-with-ghp-magazine-s-2026-ra983f6gyao1.html", "source_name": "Stock Titan", "published_at": "2026-05-18T09:38:51", "published_display": "18 May 2026 09:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INTS News | INTENSITY THERAPEUTICS INC (NASDAQ:INTS)", "summary": "This article provides recent news and analysis for Intensity Therapeutics Inc. (NASDAQ: INTS). Key updates include the company's Q1 2026 results where EPS beat expectations despite no revenue, and its recognition with GHP Magazine's 2026 Healthcare & Pharmaceutical Award. The cur", "url": "https://www.chartmill.com/stock/quote/INTS/news", "source_name": "ChartMill", "published_at": "2026-05-18T08:39:55", "published_display": "18 May 2026 08:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/intensity-therapeutics-recognized-ghp-magazines-120000408.html", "source_name": "PR Newswire", "published_at": "2026-05-14T12:00:00+00:00", "published_display": "14 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxOcnI2b2o2NThtb2x4andUM1JIOWtLSnJVLTRJRXRqZGNEV1ZoYV9GckFaSktSaEJwWWEzM3BOMHRaV1hqUEFQaUUxMUJXY2VCM0FERGhpQ0dQNzY4YTF3azVvRUh1c0twaDZFMXpJWnAtNEs5SGpGSDhxazNnLXZCNU16Z3ZsZVk5VC1rR1hVdTJLUXFvUjd3Rlh0dV9OS3VUclN0aU54Qm9kZHZRbERXRkpERkdfUDhWVDBZMzdGOUo5MnFFSzBWRWp5MWRmb0RaODB4STk2N1RIR3lBQzJoYmRha3o4Y21j?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNWFRzZU1BV2FpNlJ3ejBkOE1FT2tEbXB3WEhVLVVhWWpaSEFSYVozUHpTcWFyLXl6N25hNmVpMjhLWFBMcmtvcnBlM1VVcFBTOG1HdTZsY2R0ZThnOFpuQ01DcUhabWdfZDd1aUMzaE93SHpROG16RDR0Y2M4WWJVR3JBYXd0TmZHc3dyTXh1bDg4TkNKMTMwZ1pzeWtSRnFPTkszcw?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbkZISmFmQ0szWHhCNkNJMjRadXhURm92R3lwWk52aHlOdEh6aV9UaUR1UV9ka1RzVk42ZFFaR1NEUDhDZThpb0pqZUhFZFRxa0paZkZCSERDelZxMktxZHRYV08zR2p5dEoyRjhmbnRnWXU3ZEhtQmNzZEtNVzdkdUtVa3lhRTdpNERycXFsNGJ0R1JiazFqa3E1TF90S0s1ZUZOQmw1NDA?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did INTS Stock Plummet 25% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNjlGNWltUUNZSXdYOVctWGlYd1dHQWxoTVVnaDdPNTF1MDNFTXVDZWhHYXRRUjQxM3hUdnFGTVdSN0lhX2lvVzRxV1dYVWgwT0xBdEI0el9TYkVORmpNLVoxS09UcURYNDI1aVloUkZFX1E1b0VoS3Z0RXd4YmRzV3NhNEpJbjlrUVJhb2xqY0xQQ3N3NE1oNXI5Nk00S1pSejJBZnZ4VkZ6UmM?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Announces Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPTDdTNDBoTm9MM0p0dWFxQ09HeXB3c3JiOW9wa2JKRXBsUUM0YkIwd18yV3ZsRHpHS0cyREN4UXFERDU0VElHR0Jid1NvbXJSc3o2ZHlVR1NNWTVWd3dYY3hDWmlfMkVVdFBPcnZhbEc0X2E4MndBNTdCNWFTSDNuaTZEMnBnM1JnbXJ2VmRtVzhzaXZ6NHVVaWVSTHRTN2ZPVnEtVjZydktOeUd3?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UnitedHealth Stock Plummets 20% After Earnings. Why Soft Revenue Isn\u2019t the Only Problem.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPMTdzUkZQWG9tTW9zT3FxSWtzdkdLLUNYVkRJMDh2X1VRSlVrdmVkS3FCSVFpX210VUxVSUF1Q2FYakw1ZUxyQlpoZHZpM1RYQzBOYlpEWENxeGM1bXBZNFYxQjZRcFBpcS0tVVhRdzFTejBrVzU3aU9QQXdnYkZBMWxB?oc=5", "source_name": "Barron's", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxNZXRXUzFyektQVkdNcUZVVFhQbFI4WGFVekVWNFg0N1VlWVJJeTgwZEN3QUlENk41dzlOeGlsb0xZenltQkw0cGw3aDEyal9lWWMtQm1ZZXA5eHpnU0trWDZRNThfT1dPTXFVZGd0akJGUmVsVVQ5NjM0RUg3U0Zha0FNdGVPM3JRLWVBbmExam5xeDg3bUpCMmVZTnA3dzJvdEZDQzQ0dkpsb19WcFQ4ZmxVWjg3RWJxYW5YRkd1NGlfZE02aEhTbUp2QTd4TEFOMS1MX2dCU1hvRnFzeXNmX2RoWHVRM1laMUV3dV90QWRKZlBOMWNhbGM4Y2Q?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 65, "sentiment_summary": {"positive": 22, "negative": 3, "neutral": 40, "score": 57, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 20.7, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 11.84, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 22, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 4.78, "latest_week": "2026-07-10", "one_week_move": 12.7, "four_week_move": 32.0, "twelve_week_move": -9.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.392122, "market_dynamics_buy_signal": false, "relative_strength": -45.200205, "fair_value_gap": -92.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 37.7558, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+12.7% over one week, +32.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 10}, {"label": "Market source", "count": 9}, {"label": "PR Newswire", "count": 6}, {"label": "Stock Titan", "count": 6}, {"label": "TradingKey", "count": 5}, {"label": "Investing.com", "count": 3}, {"label": "grafa.com", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 58}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 22}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "58", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+12.7% over one week, +32.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Intensity Therapeutics restarts 61-patient breast cancer trial"}], "updated_at": "2026-07-16T03:01:59.390343+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}